Nobias Therapeutics
Tuesday, February 27, 2024
Uris
Platform for Therapeutics
Nobias Therapeutics is a biotechnology company pioneering deep phenotyping to discover advanced therapeutics. Nobias uses its cutting-edge, applied AI platform to distill disease drivers and optimal points for therapeutic intervention from rich clinical and genetic datasets, and to accelerate the development of novel therapies for a broad range of disorders. To learn more, please visit www.nobiastx.com.
State
CA
Country
United States
Website
https://www.nobiastx.com/
CEO/Top Company Official
Neil Inala
Lead Product in Development
NB-001, an investigational new drug for treatment of neuropsychiatric complications of 22q11 deletion syndrome (DiGeorge).
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
2